Palvella Therapeutics (PVLA) Research & Development (2014 - 2026)
Palvella Therapeutics (PVLA) reported Research & Development of $9.3 million for Q1 2026, up 129.11% year-over-year from $4.1 million in Q1 2025, and up 31.08% on a QoQ basis from $7.1 million in Q4 2025.
Palvella Therapeutics (PVLA) has 13 years of Research & Development data on file, last reported at $9.3 million in Q1 2026.
- Quarterly Research & Development rose 129.11% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.1 million (up 149.99% YoY) and the FY2025 annual result came in at $22.8 million, up 180.22% from the prior year.
- Research & Development rose to $9.3 million in Q1 2026 per PVLA's latest filing, from $7.1 million in the prior quarter.
- Across five years, Research & Development topped out at $14.3 million in Q2 2023 and bottomed at -$28.6 million in Q4 2023.
- The 5-year median for Research & Development is $6.8 million (2025), against an average of $5.5 million.
- The widest annual swing landed in 2024, when Research & Development plunged 92.67%; it then surged 314.02% in 2025.
- Tracing PVLA's Research & Development over 5 years: stood at $13.6 million in 2022, then slumped by 310.13% to -$28.6 million in 2023, then jumped by 108.91% to $2.5 million in 2024, then soared by 180.02% to $7.1 million in 2025, then jumped by 31.08% to $9.3 million in 2026.
- Per Business Quant, the three latest PVLA Research & Development figures stand at $9.3 million (Q1 2026), $7.1 million (Q4 2025), and $6.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 9.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.33 Mn |
| Dec 31, 2025 | 7.12 Mn |
| Sep 30, 2025 | 6.53 Mn |
| Jun 30, 2025 | 5.12 Mn |
| Mar 31, 2025 | 4.07 Mn |
| Dec 31, 2024 | 2.54 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 984,000.00 |
| Dec 31, 2023 | -28.55 Mn |
| Sep 30, 2023 | 9.60 Mn |
| Jun 30, 2023 | 14.33 Mn |
| Mar 31, 2023 | 13.42 Mn |
| Sep 30, 2022 | 13.59 Mn |
| Jun 30, 2022 | 11.95 Mn |
| Mar 31, 2022 | 14.07 Mn |
| Dec 31, 2021 | 15.36 Mn |
| Sep 30, 2021 | 18.94 Mn |
| Jun 30, 2021 | 15.80 Mn |
| Mar 31, 2021 | 16.56 Mn |
| Dec 31, 2020 | 10.62 Mn |
| Sep 30, 2020 | 11.82 Mn |
| Jun 30, 2020 | 11.33 Mn |
| Mar 31, 2020 | 12.76 Mn |
| Dec 31, 2019 | 14.12 Mn |
| Sep 30, 2019 | 13.21 Mn |
| Jun 30, 2019 | 13.37 Mn |
| Mar 31, 2019 | 14.30 Mn |
| Dec 31, 2018 | 13.00 Mn |
| Sep 30, 2018 | 11.40 Mn |
| Jun 30, 2018 | 9.16 Mn |
| Mar 31, 2018 | 7.94 Mn |
| Dec 31, 2017 | 5.27 Mn |
| Sep 30, 2017 | 6.26 Mn |
| Jun 30, 2017 | 5.40 Mn |
| Mar 31, 2017 | 5.36 Mn |
| Dec 31, 2016 | 6.92 Mn |
| Sep 30, 2016 | 4.62 Mn |
| Jun 30, 2016 | 4.50 Mn |
| Mar 31, 2016 | 3.66 Mn |
| Dec 31, 2015 | 2.94 Mn |
| Sep 30, 2015 | 2.05 Mn |
| Jun 30, 2015 | 1.73 Mn |
| Mar 31, 2015 | 1.52 Mn |
| Sep 30, 2014 | 926,596.00 |
| Jun 30, 2014 | 1.12 Mn |
| Mar 31, 2014 | 1.22 Mn |